Development
Eli Lilly and Company
LLY
$769.88
$4.200.55%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 5.24B | 4.99B | 6.50B | 5.69B | 6.24B |
| Total Depreciation and Amortization | 1.53B | 1.51B | 1.47B | 1.45B | 1.52B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 527.40M | 418.70M | -1.15B | -540.20M | -180.80M |
| Change in Net Operating Assets | -3.06B | -707.00M | -572.70M | 197.60M | -800.00K |
| Cash from Operations | 4.24B | 6.21B | 6.24B | 6.79B | 7.59B |
| Capital Expenditure | -3.45B | -2.88B | -2.52B | -2.16B | -1.85B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.04B | -327.20M | -327.20M | -327.20M | -327.20M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.66B | -1.97B | -194.90M | -929.50M | -1.58B |
| Cash from Investing | -7.15B | -5.17B | -3.05B | -3.41B | -3.76B |
| Total Debt Issued | 8.65B | 3.81B | 3.34B | 4.96B | 1.50B |
| Total Debt Repaid | 0.00 | 0.00 | -1.50B | -2.35B | -1.56B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -750.00M | -750.00M | -750.00M | -750.00M | -1.50B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.07B | -3.94B | -3.80B | -3.67B | -3.54B |
| Other Financing Activities | -335.00M | -317.10M | -315.50M | -307.50M | -308.90M |
| Cash from Financing | 3.50B | -1.19B | -3.03B | -2.12B | -5.41B |
| Foreign Exchange rate Adjustments | 168.60M | -88.90M | -97.80M | -176.40M | -167.60M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 751.60M | -236.60M | 71.60M | 1.09B | -1.75B |